RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer - PubMed
4 days ago
- #breast cancer
- #homologous recombination deficiency
- #RAD51
- RAD51-based homologous recombination deficiency (HRD) is linked to better treatment response and survival in early breast cancer.
- HRD was found in 78.4% of tumors, with 69.8% having low tumor-infiltrating lymphocytes (TILs <30%).
- Patients with HRD showed higher pathologic complete response (pCR) rates (52.3%) compared to HRR-proficient (HRP) tumors (36.4%).
- RAD51 was independently associated with pCR (p = 0.03).
- Overall survival (OS) was better in HRD patients (89.2% at 5 years) vs. HRP (82.8%, p = 0.009), especially in triple-negative TILs-low disease (p = 0.005).
- The study supports RAD51-based HRD assessment as a predictive and prognostic biomarker for early-stage breast cancer treatment decisions.